Skip to main content
Frontier Biotechnologies Inc. logo

Frontier Biotechnologies Inc. — Investor Relations & Filings

Ticker · 688221 ISIN · CNE100005XF5 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 570 across all filing types
Latest filing 2020-10-26 Governance Information
Country CN China
Listing Shanghai Stock Exchange 688221

About Frontier Biotechnologies Inc.

https://www.frontierbiotech.com/

Frontier Biotechnologies Inc. is a biopharmaceutical company focused on the research, development, and commercialization of innovative medicines, particularly in the field of anti-infectives. The company's flagship product is albuvirtide, a long-acting HIV fusion inhibitor administered via injection. This therapeutic represents a significant advancement in HIV management by providing a long-acting alternative to daily oral regimens. Frontier Biotechnologies maintains a diverse pipeline of clinical-stage candidates, including protease inhibitors developed for the treatment of COVID-19. The company leverages its proprietary technology platforms to develop long-acting peptide drugs and small molecule therapeutics targeting unmet medical needs in infectious diseases and chronic conditions. Its core operations encompass the full drug development lifecycle, from discovery and clinical trials to manufacturing and commercial distribution.

Recent filings

Filing Released Lang Actions
公司章程
Governance Information Classification · 95% confidence The document is a detailed company charter or articles of association (章程) for a publicly listed company, covering company governance, shareholder rights, board structure, share issuance, and meeting procedures. It includes sections on shareholder meetings, board of directors, management, financial accounting, and other corporate governance matters. It is not a financial report, earnings release, or announcement but a governance document that sets out the internal rules and structure of the company. Therefore, it fits the category of Governance Information (CGR). The document length and content confirm it is the full governance charter, not an announcement or summary.
2020-10-26 Chinese
首次公开发行股票并在科创板上市发行结果公告
Capital/Financing Update Classification · 95% confidence The document is titled as an "发行结果公告" which translates to "Issuance Results Announcement" for a company's initial public offering (IPO) on the STAR Market (科创板). It details the results of the stock issuance, including the number of shares issued, pricing, subscription results for strategic investors, online and offline investors, and underwriting details. It also includes detailed tables of allotments and lock-up periods. The document is an announcement of the results of a capital raising event (IPO) rather than a financial report or regulatory filing about financial performance or governance. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed issuance data, confirming it is not a mere announcement of a report publication or a regulatory filing. Confidence is high due to the clear focus on issuance results and capital raising details.
2020-10-21 Chinese
首次公开发行股票并在科创板上市招股说明书
Capital/Financing Update Classification · 95% confidence The document is a detailed disclosure related to a company's stock issuance, including extensive information about the offering, risks, financial data, and business operations. It contains detailed financial figures, descriptions of the company's products, R&D activities, and risk factors. The document references the issuance of new shares, the offering price, the listing on the Shanghai Stock Exchange Sci-Tech Innovation Board (科创板), and includes a comprehensive prospectus-like discussion of the company's business and financial condition. This matches the characteristics of a prospectus or IPO offering document, which is typically classified under Capital/Financing Update (CAP) because it relates to the company's fundraising and issuance of new shares. It is not an Annual Report, Interim Report, or Earnings Release, nor is it a simple announcement or certification. The length and detail confirm it is the full document, not just an announcement. Therefore, the best fitting category is Capital/Financing Update (CAP).
2020-10-21 Chinese
首次公开发行股票并在科创板上市网下初步配售结果及网上中签结果公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the initial public offering (IPO) of shares by 前沿生物药业(南京)股份有限公司 on the Shanghai Stock Exchange's STAR Market (科创板). It includes information about the strategic placement, offline and online subscription results, allocation details, pricing, underwriting, and payment instructions. The document contains extensive data on share allocation, subscription numbers, and investor details. It is not a financial report like an annual or interim report, nor is it a transcript, audit, or management report. It is a capital market announcement related to the company's fundraising and share issuance activities. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length and detail confirm it is not a mere announcement of a report but a substantive update on financing activities.
2020-10-19 Chinese
首次公开发行股票并在科创板上市网上发行申购情况及中签率公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the initial public offering (IPO) of shares by 前沿生物药业(南京)股份有限公司, detailing the subscription situation, allocation results, and lottery for share allotment. It includes information about the underwriting, subscription rates, allocation mechanisms, and payment instructions. The document does not contain financial statements or detailed financial performance data, nor is it a transcript or presentation. It is a regulatory announcement about the IPO subscription and allocation process, which fits best under the category of Regulatory Filings (RNS) as it is a general regulatory announcement and does not fit other specific categories like Capital/Financing Update (CAP) which usually covers ongoing financing activities rather than IPO subscription results.
2020-10-18 Chinese
瑞银证券有限责任公司关于前沿生物药业(南京)股份有限公司首次公开发行股票并在科创板上市之战略投资者配售资格的专项核查报告
Audit Report / Information Classification · 95% confidence The document is a detailed report issued by UBS Securities Co., Ltd. regarding the special verification of the strategic investor placement qualification for the initial public offering (IPO) and listing of Qianyan Biopharmaceutical (Nanjing) Co., Ltd. on the STAR Market of the Shanghai Stock Exchange. It includes references to regulatory approvals from the Shanghai Stock Exchange and the China Securities Regulatory Commission, details about the internal decision-making procedures of the issuer, the strategic investor's qualifications, subscription agreements, and compliance opinions from legal counsel and the lead underwriter. The document is a standalone verification report related to the IPO process and strategic investor placement, not an announcement or a summary. It does not contain financial statements or earnings data, so it is not an Annual Report (10-K) or Interim Report (IR). It is not a general regulatory filing or announcement but a specific audit/verification report related to the IPO. Therefore, the most appropriate classification is Audit Report / Information (AR). The document length (4982 characters) supports it being a full report rather than a brief announcement. FY 2020
2020-10-14 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.